BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/26/2014 4:36:00 PM | Browse: 899 | Download: 616
Publication Name World Journal of Gastroenterology
Manuscript ID 7240
Country/Territory Japan
Received
2013-11-10 12:47
Peer-Review Started
2013-11-10 19:21
To Make the First Decision
2013-12-04 09:10
Return for Revision
2013-12-16 10:54
Revised
2013-12-18 21:52
Second Decision
2014-02-20 09:06
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-02-20 09:31
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-05-14 14:33
Publish the Manuscript Online
2014-06-06 16:55
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype
Manuscript Source Invited Manuscript
All Author List Mitsushige Sugimoto and Takahisa Furuta
Funding Agency and Grant Number
Funding Agency Grant Number
Ministry of Education, Culture, Sports, Science and Technology of Japan 22790640
Ministry of Education, Culture, Sports, Science and Technology of Japan 24590912
Corresponding Author Mitsushige Sugimoto, MD, PhD, First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan. mitsu@hama-med.ac.jp
Key Words Helicobacter pylori; Tailored eradication therapy; Proton pomp inhibitor; Cytochrome P450 2C19; Clarithromycin
Core Tip The eradication for Helicobacter pylori infection is mainly influenced by antibiotic susceptibility and insufficient acid inhibition [e.g., cytochrome P450 2C19 (CYP2C19) genotype, proton pump inhibitor (PPI) dose, and PPI treatment schedule]. When a PPI is administered to CYP2C19 rapid metabolizers and intermediate metabolizers, plasma levels of PPIs cannot be maintained between once-daily doses. The intragastric pH attained with four-times-daily-dosing of PPI is significantly higher than those observed when PPI is administered as once-daily-dosing of four-fold doses or twice-daily-dosing of two-fold doses. We describe a tailored treatment that was designed according to pharmacogenomics and antimicrobial susceptibility to achieve an eradication rate exceeding 95%, irrespective of different CYP2C19 genotypes.
Publish Date 2014-06-06 16:55
Citation Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J Gastroenterol 2014; 20(21): 6400-6411
URL http://www.wjgnet.com/1007-9327/full/v20/i21/6400.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i21.6400
Full Article (PDF) WJG-20-6400.pdf
Full Article (Word) WJG-20-6400.doc
Manuscript File 7240-Review.docx
Answering Reviewers 7240-Answering reviewers.pdf
Copyright License Agreement 7240-Copyright assignment.pdf
Peer-review Report 7240-Peer reviewer(s).pdf
Scientific Editor Work List 7240-Scientific editor work list.doc